Mark R Wills

List of Publications by Year
in descending order

70 papers	5,263 citations	117625 34 h-index	95266 68 g-index
73 all docs	73 docs citations	73 times ranked	8321 citing authors

#	Article	IF	Citations
1	Whole bloodâ€based measurement of SARSâ€CoVâ€2â€specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solidâ€organ cancers. Immunology, 2022, 165, 250-259.	4.4	21
2	B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination. Cell Reports, 2022, 38, 110393.	6.4	29
3	Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus. Journal of Clinical Investigation, 2021, 131, .	8.2	17
4	Comparative Cell Surface Proteomic Analysis of the Primary Human T Cell and Monocyte Responses to Type I Interferon. Frontiers in Immunology, 2021, 12, 600056.	4.8	7
5	Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	25
6	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 2021, 593, 136-141.	27.8	648
7	Latent Cytomegalovirus-Driven Recruitment of Activated CD4+ T Cells Promotes Virus Reactivation. Frontiers in Immunology, 2021, 12, 657945.	4.8	10
8	HCMV Antivirals and Strategies to Target the Latent Reservoir. Viruses, 2021, 13, 817.	3.3	25
9	A BMPR2/YY1 Signaling Axis Is Required for Human Cytomegalovirus Latency in Undifferentiated Myeloid Cells. MBio, 2021, 12, e0022721.	4.1	11
10	Longitudinal analysis reveals that delayed bystander CD8+ TÂcell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity, 2021, 54, 1257-1275.e8.	14.3	230
11	Targeting the latent human cytomegalovirus reservoir for T-cell-mediated killing with virus-specific nanobodies. Nature Communications, 2021, 12, 4436.	12.8	16
12	Using Primary Human Cells to Analyze Human Cytomegalovirus Biology. Methods in Molecular Biology, 2021, 2244, 51-81.	0.9	9
13	Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?. Frontiers in Cellular and Infection Microbiology, 2020, 10, 329.	3.9	10
14	The CD4+ T Cell Response to Human Cytomegalovirus in Healthy and Immunocompromised People. Frontiers in Cellular and Infection Microbiology, 2020, 10, 202.	3.9	53
15	Advances in cytomegalovirus (CMV) biology and its relationship to health, diseases, and aging. GeroScience, 2020, 42, 495-504.	4.6	29
16	Assessing Anti-HCMV Cell Mediated Immune Responses in Transplant Recipients and Healthy Controls Using a Novel Functional Assay. Frontiers in Cellular and Infection Microbiology, 2020, 10, 275.	3.9	9
17	Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet, The, 2020, 395, 888-898.	13.7	98
18	Killer cell proteases can target viral immediate-early proteins to control human cytomegalovirus infection in a noncytotoxic manner. PLoS Pathogens, 2020, 16, e1008426.	4.7	9

#	Article	IF	Citations
19	Human cytomegalovirus major immediate early transcripts arise predominantly from the canonical major immediate early promoter in reactivating progenitor-derived dendritic cells. Journal of General Virology, 2020, 101, 635-644.	2.9	13
20	Human Cytomegalovirus Upregulates Expression of HCLS1 Resulting in Increased Cell Motility and Transendothelial Migration during Latency. IScience, 2019, 20, 60-72.	4.1	15
21	Distinct Roles of Extracellular Domains in the Epstein-Barr Virus-Encoded BILF1 Receptor for Signaling and Major Histocompatibility Complex Class I Downregulation. MBio, 2019, 10, .	4.1	18
22	Generation, maintenance and tissue distribution of T cell responses to human cytomegalovirus in lytic and latent infection. Medical Microbiology and Immunology, 2019, 208, 375-389.	4.8	43
23	A novel, sensitive dual-indicator cell line for detection and quantification of inducible, replication-competent latent HIV-1 from reservoir cells. Scientific Reports, 2019, 9, 19325.	3.3	1
24	Interferon-Responsive Genes Are Targeted during the Establishment of Human Cytomegalovirus Latency. MBio, 2019, 10, .	4.1	33
25	An iPSC-Derived Myeloid Lineage Model of Herpes Virus Latency and Reactivation. Frontiers in Microbiology, 2019, 10, 2233.	3.5	18
26	No evidence of ongoing evolution in replication competent latent HIV-1 in a patient followed up for two years. Scientific Reports, 2018, 8, 2639.	3.3	14
27	Extracellular Lactate: A Novel Measure of T Cell Proliferation. Journal of Immunology, 2018, 200, 1220-1226.	0.8	39
28	Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9353-E9361.	7.1	35
29	Nanopore sequencing and full genome de novo assembly of human cytomegalovirus TB40/E reveals clonal diversity and structural variations. BMC Genomics, 2018, 19, 577.	2.8	17
30	Human Cytomegalovirus (HCMV)-Specific CD4 ⁺ T Cells Are Polyfunctional and Can Respond to HCMV-Infected Dendritic Cells In Vitro. Journal of Virology, 2017, 91, .	3.4	71
31	A highly reproducible quantitative viral outgrowth assay for the measurement of the replication-competent latent HIV-1 reservoir. Scientific Reports, 2017, 7, 43231.	3.3	36
32	Latency-Associated Expression of Human Cytomegalovirus US28 Attenuates Cell Signaling Pathways To Maintain Latent Infection. MBio, 2017, 8, .	4.1	82
33	CMV immune evasion and manipulation of the immune system with aging. GeroScience, 2017, 39, 273-291.	4.6	69
34	Modulation of Human Leukocyte Antigen-C by Human Cytomegalovirus Stimulates KIR2DS1 Recognition by Natural Killer Cells. Frontiers in Immunology, 2017, 8, 298.	4.8	45
35	Latent Cytomegalovirus (CMV) Infection Does Not Detrimentally Alter T Cell Responses in the Healthy Old, But Increased Latent CMV Carriage Is Related to Expanded CMV-Specific T Cells. Frontiers in Immunology, 2017, 8, 733.	4.8	59
36	Human Cytomegalovirus Delays Neutrophil Apoptosis and Stimulates the Release of a Prosurvival Secretome. Frontiers in Immunology, 2017, 8, 1185.	4.8	22

#	Article	IF	Citations
37	Innovations in the quantitative virus outgrowth assay and its use in clinical trials. Retrovirology, 2017, 14, 58.	2.0	6
38	HCMV activation of ERK-MAPK drives a multi-factorial response promoting the survival of infected myeloid progenitors. Journal of Molecular Biochemistry, 2017, 6, 13-25.	0.1	11
39	The Expression of Human Cytomegalovirus MicroRNA MiR-UL148D during Latent Infection in Primary Myeloid Cells Inhibits Activin A-triggered Secretion of IL-6. Scientific Reports, 2016, 6, 31205.	3.3	69
40	Leukocyte Immunoglobulin-Like Receptor 1-Expressing Human Natural Killer Cell Subsets Differentially Recognize Isolates of Human Cytomegalovirus through the Viral Major Histocompatibility Complex Class I Homolog UL18. Journal of Virology, 2016, 90, 3123-3137.	3.4	27
41	Human cytomegalovirus miR-UL112-1 promotes the down-regulation of viral immediate early-gene expression during latency to prevent T-cell recognition of latently infected cells. Journal of General Virology, 2016, 97, 2387-2398.	2.9	43
42	How understanding immunology contributes to managing CMV disease in immunosuppressed patients: now and in future. Medical Microbiology and Immunology, 2015, 204, 307-316.	4.8	41
43	The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?. Cellular and Molecular Immunology, 2015, 12, 128-138.	10.5	107
44	Human Cytomegalovirus Latency: Targeting Differences in the Latently Infected Cell with a View to Clearing Latent Infection. New Journal of Science, 2014, 2014, 1-10.	1.0	21
45	Ribosome Profiling Reveals Pervasive Translation Outside of Annotated Protein-Coding Genes. Cell Reports, 2014, 8, 1365-1379.	6.4	591
46	Latency-Associated Viral Interleukin-10 (IL-10) Encoded by Human Cytomegalovirus Modulates Cellular IL-10 and CCL8 Secretion during Latent Infection through Changes in the Cellular MicroRNA hsa-miR-92a. Journal of Virology, 2014, 88, 13947-13955.	3.4	53
47	Human Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4+ T Cells. PLoS Pathogens, 2013, 9, e1003635.	4.7	68
48	The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with MHC-I mRNA degradation. EMBO Journal, 2012, 31, 3596-3606.	7.8	74
49	Human cytomegalovirus latency alters the cellular secretome, inducing cluster of differentiation (CD)4⁺T-cell migration and suppression of effector function. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14538-14543.	7.1	78
50	Efficient Human Cytomegalovirus Reactivation Is Maturation Dependent in the Langerhans Dendritic Cell Lineage and Can Be Studied using a CD14⁺Experimental Latency Model. Journal of Virology, 2012, 86, 8507-8515.	3.4	45
51	Human cytomegalovirus immunity and immune evasion. Virus Research, 2011, 157, 151-160.	2.2	225
52	Preface. Virus Research, 2011, 157, 127.	2.2	0
53	Intracellular Sequestration of the NKG2D Ligand ULBP3 by Human Cytomegalovirus. Journal of Immunology, 2010, 185, 1093-1102.	0.8	61
54	NKG2D Ligand MICA Is Retained in thecis-Golgi Apparatus by Human Cytomegalovirus Protein UL142. Journal of Virology, 2009, 83, 12345-12354.	3.4	105

#	Article	IF	Citations
55	Dynamics of T cell memory in human cytomegalovirus infection. Medical Microbiology and Immunology, 2008, 197, 83-96.	4.8	72
56	Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1656-1661.	7.1	159
57	Natural killer cell evasion by an E3 ubiquitin ligase from Kaposi's sarcoma-associated herpesvirus. Biochemical Society Transactions, 2008, 36, 459-463.	3.4	31
58	Rapid CD8+ T Cell Repertoire Focusing and Selection of High-Affinity Clones into Memory Following Primary Infection with a Persistent Human Virus: Human Cytomegalovirus. Journal of Immunology, 2007, 179, 3203-3213.	0.8	124
59	Differential costimulation through CD137 (4â€“1BB) restores proliferation of human virus-specific â€œeffector memoryâ€•(CD28â¯ CD45RAHI) CD8+ T cells. Blood, 2007, 110, 4360-4366.	1.4	82
60	Regulation of NKG2D Ligand Gene Expression. Human Immunology, 2006, 67, 159-169.	2.4	97
61	Large HIV-specific CD8+ cytotoxic T-lymphocyte (CTL) clones reduce their overall size but maintain high frequencies of memory CTL following highly active antiretroviral therapy. Immunology, 2006, 118, 25-38.	4.4	14
62	Human Cytomegalovirus Encodes an MHC Class I-Like Molecule (UL142) That Functions to Inhibit NK Cell Lysis. Journal of Immunology, 2005, 175, 7457-7465.	0.8	125
63	Long-Term Stable Expanded Human CD4+ T Cell Clones Specific for Human Cytomegalovirus Are Distributed in Both CD45RAhigh and CD45ROhigh Populations. Journal of Immunology, 2004, 173, 5843-5851.	0.8	40
64	Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. Blood Reviews, 2003, 17, 259-264.	5.7	28
65	Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation. Blood, 2003, 102, 3427-3438.	1.4	59
66	Identification of Naive or Antigen-Experienced Human CD8+ T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8+ T Cell Response. Journal of Immunology, 2002, 168, 5455-5464.	0.8	189
67	Functional Heterogeneity and High Frequencies of Cytomegalovirus-Specific CD8⁺T Lymphocytes in Healthy Seropositive Donors. Journal of Virology, 2000, 74, 8140-8150.	3.4	396
68	The Memory Cytotoxic T-Lymphocyte (CTL) Response to Human Cytomegalovirus Infection Contains Individual Peptide-Specific CTL Clones That Have Undergone Extensive Expansion In Vivo. Journal of Virology, 1999, 73, 2099-2108.	3.4	186
69	Progressive loss of IL-2-expandable HIV-1-specific cytotoxic T lymphocytes during asymptomatic HIV infection. European Journal of Immunology, 1998, 28, 3564-3576.	2.9	15
70	HCMV: immunobiology and host response. , 0, , 780-794.		5